Security record · archived quarter
COLL
Collegium Pharmaceutical, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
12Tracked holders
—Δ holders
3.67MShares held
$118.10MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 98 | +3 | 27.25M | $986.22M | +8 | −5 |
| Q1 2026 | 98 | -1 | 28.14M | $930.88M | +7 | −9 |
| Q4 2025 | 100 | 0 | 26.92M | $1.25B | +1 | — |
| Q3 2025 | 19 | +2 | 14.79M | $517.39M | +2 | — |
| Q2 2025 | 14 | +1 | 12.36M | $365.37M | +1 | — |
| Q1 2025 | 10 | -1 | 5.48M | $163.49M | — | −1 |
| Q4 2024 | 11 | -1 | 5.00M | $143.28M | — | −1 |
| Q3 2024 | 11 | -1 | 3.77M | $145.78M | — | −1 |
| Q2 2024 | 12 | — | 3.67M | $118.10M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 1.53M | — | $49.31M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 770.12K | — | $24.80M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 770.12K | — | $24.80M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Millennium Management ✦ | 303.87K | — | $9.78M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 254.77K | — | $8.20M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 198.86K | — | $6.40M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 172.67K | — | $5.56M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 172.67K | — | $5.56M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 101.96K | — | $3.28M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 101.96K | — | $3.28M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 97.86K | — | $3.15M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 97.86K | — | $3.15M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Arrowstreet Capital ✦ | 72.74K | — | $2.34M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Marshall Wace ✦ | 70.96K | — | $2.29M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Marshall Wace ✦ | 70.96K | — | $2.29M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 61.42K | — | $1.98M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 30.86K | — | $994,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 5.10M shares, $5.91M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API